RxDoctor Payments Data

Olawale Olatunji, MD

Cardiovascular Disease · Beckley, WVNPI 1154390078

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 50 payments — averaging $33.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • AstraZeneca$132
  • Inspire Medical Systems, Inc.$103
  • Pfizer$85
  • Genentech USA, Inc.$71
  • Johnson & Johnson$53
  • plus $134 from 4 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 30th percentile of 100 cardiovascular disease providers in West Virginia.

See all cardiovascular disease providers in West Virginia

Medicare billing

Part B allowed, 2024
$60,226
Medicare patients
680
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$20,733
EliquisApixaban25$19,198
EntrestoSacubitril/Valsartan18$16,432
Repatha SureclickEvolocumab11$12,070
FarxigaDapagliflozin Propanediol13$9,306
Metoprolol Succinate239$1,864
Isosorbide Mononitrate ErIsosorbide Mononitrate64$515
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$211
ClopidogrelClopidogrel Bisulfate20$112
Rosuvastatin Calcium19$84
Atorvastatin Calcium22$82
Losartan Potassium16$75
Lisinopril20$75
FenofibrateFenofibrate Nanocrystallized22$71
Amlodipine Besylate36$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$38$20,73331 claims
PfizerEliquis$85$19,19825 claims
NovartisEntresto$46$16,43218 claims
AstraZenecaFarxiga$132$9,30613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 100 cardiovascular disease providers in West Virginia.

Other cardiovascular disease in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →